Biocon Ltd. | BIOCON | NSE - Pharmaceuticals
INR in Million. Fiscal year ends in March. Figures are consolidated and restated..
Upgrade Membership to see 10 year accurate financial statements.
Chart | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Cash and cash equiva... |
![]() | 10,443 | 13,228 | 10,572 | 9,986 | 20,154 |
Short-term investment |
![]() | 10,650 | 6,114 | 8,293 | 8,576 | 12,609 |
Accounts receivables |
![]() | 8,832 | 10,639 | 12,918 | 12,237 | 12,176 |
Inventories |
![]() | 6,353 | 7,225 | 10,316 | 14,359 | 18,666 |
Deferred income taxes |
![]() | 0 | 0 | 0 | 0 | 0 |
Other current assets |
![]() | 4,199 | 4,280 | 6,129 | 8,092 | 12,399 |
Total current assets |
![]() | 40,477 | 41,486 | 48,228 | 53,250 | 76,004 |
Gross property plant... |
![]() | 35,529 | 36,297 | 42,527 | 53,932 | 55,573 |
Accumulated Depriciat... |
![]() | 0 | 0 | 0 | 0 | 0 |
Net property, plant and Eq... |
![]() | 35,529 | 36,297 | 42,527 | 53,932 | 55,573 |
Work in Progress |
![]() | 5,327 | 7,789 | 12,869 | 15,765 | 22,535 |
Miscellaneous Investment |
![]() | 2,980 | 1,995 | 2,926 | 1,906 | 10,097 |
Deferred income taxes |
![]() | 2,870 | 3,207 | 4,940 | 6,097 | 5,725 |
Intangible assets |
![]() | 3,523 | 5,673 | 8,039 | 10,427 | 11,736 |
Goodwill |
![]() | 264 | 264 | 264 | 264 | 264 |
Other long-term assets |
![]() | 2,972 | 3,186 | 2,131 | 2,797 | 3,289 |
Total non-current assets |
![]() | 53,465 | 58,411 | 73,696 | 91,188 | 109,219 |
Total assets |
![]() | 93,942 | 99,897 | 121,924 | 144,438 | 185,223 |
Short-term debt |
![]() | 972 | 1,303 | 2,612 | 6,676 | 5,942 |
Accounts Payable... |
![]() | 7,397 | 10,053 | 11,983 | 13,251 | 15,139 |
Provisions |
![]() | 468 | 465 | 805 | 1,030 | 1,094 |
Taxes Payable |
![]() | 964 | 891 | 1,238 | 1,279 | 1,524 |
Deferred Revenues |
![]() | 0 | 0 | 0 | 0 | 0 |
Capital Leases |
![]() | 0 | 0 | 0 | 68 | 84 |
Other current liabilities |
![]() | 6,982 | 8,701 | 13,738 | 17,776 | 18,318 |
Total current liabilities |
![]() | 16,783 | 21,413 | 30,376 | 40,080 | 42,101 |
Long-term debt |
![]() | 21,082 | 17,898 | 15,416 | 12,222 | 29,616 |
Investments Liabilities |
![]() | 61 | 183 | 350 | 1,461 | 618 |
Deferred tax liabilities |
![]() | 0 | 0 | 0 | 298 | 323 |
Provisions |
![]() | 360 | 493 | 661 | 858 | 1,062 |
Capital Leases |
![]() | 0 | 0 | 0 | 831 | 1,141 |
Other longterm liabilities |
![]() | 3,518 | 3,425 | 8,052 | 14,857 | 25,286 |
Total non-current liabilities |
![]() | 25,021 | 21,999 | 24,479 | 30,527 | 58,046 |
Total liabilities |
![]() | 41,804 | 43,412 | 54,855 | 70,607 | 100,147 |
Share Capital |
![]() | 1,000 | 3,000 | 3,000 | 6,000 | 6,000 |
Share premium |
![]() | 0 | 0 | 0 | 0 | 0 |
Retained earnings |
![]() | 47,377 | 48,808 | 57,980 | 61,058 | 70,269 |
Accumulated other equity |
![]() | 0 | 0 | 0 | 0 | 0 |
Preferred Stock |
![]() | 0 | 0 | 0 | 0 | 0 |
Minority Interest |
![]() | 3,761 | 4,677 | 6,089 | 6,773 | 8,807 |
Total Equity |
![]() | 52,138 | 56,485 | 67,069 | 73,831 | 85,076 |
Total Liabilities and Equity |
![]() | 93,942 | 99,897 | 121,924 | 144,438 | 185,223 |
Cash per Share |
![]() | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade |
Cash, Current Inv Per share |
![]() | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade |